Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 74, Issue 6, 2014, Pages 477-484

  Sandhu, Noreen ^a   Karlsen, Mona A ^b   Hogdall, Claus ^c   Laursen, Inga A ^a   Christensen, Ib J ^c   Hogdall, Estrid V S ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biomarker; Cancer antigen 125; Chemiluminescent immunoassay; EDTA plasma; Human epididymis protein 4; Serum; Specimen handling

Indexed keywords

CA 125 ANTIGEN; EDETIC ACID; HUMAN EPIDIDYMIS PROTEIN 4; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ARTICLE; BLOOD CLOTTING; BLOOD STORAGE; CANCER PATIENT; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FREEZE THAWING; HUMAN; OVARY CANCER; PROTEIN BLOOD LEVEL; PROTEIN STABILITY; REACTION TIME; TEMPERATURE; BLOOD; METABOLISM; OVARY TUMOR; REPRODUCIBILITY;

CA-125 ANTIGEN; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEINS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907045738     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2014.903430     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Høg dall CK, Nielsen MLS. Taaning L. Year rapport 2011. Danish Gynecologic Cancer Database. A nationwide clinical database for cancer in ovaries, uterus and cervix. L æ geforeningens forlag, Copenhagen. ISNN: 1903-0223 (online) 2012; Table 14.1.1.
3. Engholm G, Storm H H, Ferlay J, Christensen N, Gjerstorff ML, Johannesen TB, Klintå, Milter MC, Køtlum JE, Pukkala E, Ólafsdóttir E, NORDCAN: Cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 4.0. Association of the Nordic Cancer Registries. Danish Cancer Society 2011. http://www-dep. iarc.fr/nordcan.htm.
4. Kræftprofil -æggestokkræf t 2000-2006. 2009. Sundhedsstyrelsen. http://www.sst.dk/publ/Publ2009/EPT/Kraeftprofiler/Kraeftprofil-Aeggestokkraeft2000-2006.pdf.
5. OBrien T J, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001; 22: 348-66.
6. Yin B W, Lloyd K O. Molecular cloning of the CA 125 ovarian cancer antigen: identification as a new mucin, MUC16. JBiol Chem 2001; 276: 27371-5.
7. Bast R C Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-7.
8. Kabawat SE, Bast RC Jr, Bhan A K, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epitheliumrelated antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983; 2: 275-85.
9. Bast RC Jr, Knapp RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 1985; 19: 354-6.
10. Einhorn N, Bast RC Jr, Knapp RC, Tjernberg B, Zurawski VR Jr. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986; 67: 414-6.
11. Høg dall C K, Mogensen O, Tabor A, Mogensen B, Jakobsen AK, Nørgaard-Pedersen B, Larsen SO, Clemmensen I. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors. Gynecol Oncol 1995; 56: 22-8.
12. Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK, Bristow RE. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005; 23: 9338-43.
13. Duffy MJ, Bonfrer JM, Kulpa J, Rustin G J, Soletormos G, Torre GC, Tuxen MK, Zwirner M. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15: 679-91.
14. Riedinger JM, Bonnetain F, Basuyau JP, Eche N, Larbre H, Dalifard I, Wafflart J, Ricolleau G, Pichon MF. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007; 18: 881-5.
15. Goonewardene YI, Hall M R, Rustin G J. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA 125 concentrations. Lancet Oncol 2007; 8: 813-21.
16. Bouchard D, Morisset D, Bourbonnais Y, Tremblay G M. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7: 167-74.
17. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162-9.
18. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695-700.
19. Moore R G, Brown AK, Miller M C, Skates S, Allard W J, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108: 402-8.
20. Moore RG, McMeekin DS, Brown A K, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ. Anovel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40-6.
21. Karlsen MA, Sandhu N, Høg dall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2012; 127: 379-83.
22. Gao YC, Yuan ZB, Yang YD, Lu HK. Effect of freezethaw cycles on serum measurements of AFP, CEA, CA125 and CA19-9. Scand J Clin Lab Invest 2007; 67: 741-7.
23. Sparholt M H, Høg dall C K, Nedergaard L, Heeran M C, Christensen IJ, Høgdall EV. Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic? APMIS 2013; 121: 38-44.
24. Banfi G, Parma P, Pontillo M. Stability of tumor markers CA 19.9, CA 125, and CA 15.3 in serum obtained from plain tubes and tubes containing thixotropic gel separator. Clin Chem 1997; 43: 2430-1.
25. Høg dall E V, Johansen J S, Kjaer S K, Price P A, Blaakjaer J, Høgdall CK. Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 2000; 60: 247-51.
26. Hogdall E V, Hogdall C K, Kjaer S K, Xu F, Yu Y, Bast R C, Blaakaer J, Jacobs IJ. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. Clin Chem 1999; 45: 692-4.
27. Begum FD, Høg dall E, Christensen IJ, Kjaer SK, Blaakaer J, Christensen L, Høgdall C. Serum tetranectin is a significant prognostic marker in ovarian cancer patients. Acta Obstet Gynecol Scand 2010; 89: 190-8.
28. Høg dall CK, Høgdall EV, Hørding U, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K. Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest 1993; 53: 741-6.